Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad052 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Matthijs P Raadsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, Viral Vaccines, Coronavirus Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands.
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
- Department for Clinical Immunology of Infectious Diseases, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.
- German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
- First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
ORCID-Profile: Matthijs P Raadsen, Marion Koopmans, Bart L Haagmans
Zitieren
APA
Raadsen, M. P., Dahlke, C., Fathi, A., Lamers, M. M., van den Doel, P., Zaeck, L. M., van Royen, M. E., de Bruin, E., Sikkema, R., Koopmans, M., van Gorp, E. C. M., Sutter, G., de Vries, R. D., Addo, M. M., & Haagmans, B. L. (2023). Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad052
Vancouver
Raadsen MP, Dahlke C, Fathi A, Lamers MM, van den Doel P, Zaeck LM, et al. Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad052
BibTeX
@article{Raadsen2023,
author = {Raadsen, Matthijs P and Dahlke, Christine and Fathi, Anahita and Lamers, Mart M and van den Doel, Petra and Zaeck, Luca M and van Royen, Martin E and de Bruin, Erwin and Sikkema, Reina and Koopmans, Marion and van Gorp, Eric C M and Sutter, Gerd and de Vries, Rory D and Addo, Marylyn M and Haagmans, Bart L},
title = {Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad052}
}
EUVIMED